Press Releases —
ADVANZ PHARMA Acquires Global Rights to Rare Disease Specialty Brand Zavesca®
13 Oct 2025
Learn more
News
-
-
Press Releases —
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06 Oct 2025Learn more -
Press Releases —
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
28 May 2025Learn more -
Press Releases —
ADVANZ PHARMA and PHARMATHEN Expand Strategic Partnership with Exclusive License and Supply Agreement
15 May 2025Learn more -
Press Releases —
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
04 Nov 2024Learn more -
Press Releases —
ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2023-2024
04 Oct 2024Learn more -
Press Releases —
ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation
27 Aug 2024Learn more -
Press Releases —
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
15 Aug 2024Learn more